Compare SGMO & JHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SGMO | JHS |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.2M | 136.5M |
| IPO Year | 2000 | 1994 |
| Metric | SGMO | JHS |
|---|---|---|
| Price | $0.40 | $11.45 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.75 | N/A |
| AVG Volume (30 Days) | ★ 6.4M | 13.9K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,567,000.00 | N/A |
| Revenue This Year | $4.79 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 88.60 | N/A |
| 52 Week Low | $0.35 | $10.62 |
| 52 Week High | $1.06 | $12.09 |
| Indicator | SGMO | JHS |
|---|---|---|
| Relative Strength Index (RSI) | 47.61 | 32.77 |
| Support Level | $0.36 | $11.38 |
| Resistance Level | $0.56 | $11.66 |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 24.56 | 14.29 |
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
John Hancock Income Securities Trust is a United States-based closed-end diversified management investment company. Its main objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.